MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

NCT02551055 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Stopped Business Decision; No Safety Or Efficacy Concerns.

Conditions

Advanced and Metastatic Gastric or Gastroesophageal Adenocarcinoma

Interventions

DRUG: MLN1117
DRUG: TAK-659
DRUG: Alisertib
DRUG: Paclitaxel
DRUG: Docetaxel

Sponsor

Millennium Pharmaceuticals, Inc.